Q1 2019 EPS Estimates for Collegium Pharmaceutical Inc (COLL) Reduced by Analyst

Collegium Pharmaceutical Inc (NASDAQ:COLL) – William Blair decreased their Q1 2019 earnings per share estimates for Collegium Pharmaceutical in a report released on Tuesday, January 8th. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings of ($0.43) per share for the quarter, down from their prior forecast of ($0.40). William Blair also issued estimates for Collegium Pharmaceutical’s Q2 2019 earnings at ($0.24) EPS, Q3 2019 earnings at ($0.18) EPS, Q4 2019 earnings at ($0.11) EPS, FY2019 earnings at ($0.96) EPS and FY2020 earnings at $0.73 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The firm had revenue of $70.20 million for the quarter, compared to analysts’ expectations of $74.79 million. During the same period last year, the firm earned ($0.45) earnings per share. Collegium Pharmaceutical’s revenue for the quarter was up 485.0% on a year-over-year basis.

COLL has been the topic of a number of other reports. ValuEngine downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 4th. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, October 23rd. Cantor Fitzgerald set a $35.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Friday, November 30th. Finally, HC Wainwright reissued a “buy” rating on shares of Collegium Pharmaceutical in a research note on Monday, September 17th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Collegium Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $30.43.

Shares of COLL stock opened at $15.87 on Thursday. The company has a current ratio of 0.78, a quick ratio of 0.75 and a debt-to-equity ratio of 4.17. Collegium Pharmaceutical has a 12 month low of $13.70 and a 12 month high of $29.90. The stock has a market cap of $622.39 million, a price-to-earnings ratio of -6.43 and a beta of 0.52.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $16.60, for a total value of $415,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 75,000 shares of company stock worth $1,282,750 over the last three months. Insiders own 13.87% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA grew its holdings in shares of Collegium Pharmaceutical by 192.3% in the second quarter. Granahan Investment Management Inc. MA now owns 127,460 shares of the specialty pharmaceutical company’s stock valued at $3,040,000 after purchasing an additional 83,860 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Collegium Pharmaceutical by 1,171.8% in the second quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock valued at $8,611,000 after purchasing an additional 332,647 shares in the last quarter. LPL Financial LLC grew its holdings in shares of Collegium Pharmaceutical by 4.5% in the third quarter. LPL Financial LLC now owns 200,863 shares of the specialty pharmaceutical company’s stock valued at $2,961,000 after purchasing an additional 8,558 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Collegium Pharmaceutical by 203.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 155,374 shares of the specialty pharmaceutical company’s stock valued at $3,706,000 after purchasing an additional 104,255 shares in the last quarter. Finally, Strs Ohio grew its holdings in shares of Collegium Pharmaceutical by 51.6% in the third quarter. Strs Ohio now owns 50,800 shares of the specialty pharmaceutical company’s stock valued at $748,000 after purchasing an additional 17,300 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Story: What are earnings reports?

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply